☰

Tadas S. Vasaitis, Ph.D. - Publications

Affiliations: 
2007 Pharmacology and Experimental Therapeutics Physiology Social Work University of Maryland School of Medicine, Baltimore, MD, United States 
Area:
Pharmacology, Oncology
Tree Info Similar researchers PubMed Report error

17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Kwegyir-Afful AK, Ramalingam S, Ramamurthy VP, Purushottamachar P, Murigi FN, Vasaitis TS, Huang W, Kane MA, Zhang Y, Ambulos N, Tiwari S, Srivastava P, Nnane IP, Hussain A, Qiu Y, et al. Galeterone and The Next Generation Galeterone Analogs, VNPP414 and VNPP433-3β Exert Potent Therapeutic Effects in Castration-/Drug-Resistant Prostate Cancer Preclinical Models In Vitro and In Vivo. Cancers. 11. PMID 31653008 DOI: 10.3390/Cancers11111637  0.528
2019 Ramalingam S, Ramamurthy VP, Gediya LK, Murigi FN, Purushottamachar P, Huang W, Choi EY, Zhang Y, Vasaitis TS, Kane MA, Lapidus RG, Njar VCO. The Novel Mnk1/2 Degrader and Apoptosis Inducer VNLG-152 Potently Inhibits TNBC Tumor Growth and Metastasis. Cancers. 11. PMID 30832411 DOI: 10.3390/Cancers11030299  0.311
2013 Purushottamachar P, Godbole AM, Gediya LK, Martin MS, Vasaitis TS, Kwegyir-Afful AK, Ramalingam S, Ates-Alagoz Z, Njar VC. Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer. Journal of Medicinal Chemistry. 56: 4880-98. PMID 23713567 DOI: 10.1021/Jm400048V  0.591
2011 Bruno RD, Vasaitis TS, Gediya LK, Purushottamachar P, Godbole AM, Ates-Alagoz Z, Brodie AM, Njar VC. Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model. Steroids. 76: 1268-79. PMID 21729712 DOI: 10.1016/J.Steroids.2011.06.002  0.65
2011 Vasaitis TS, Bruno RD, Njar VC. CYP17 inhibitors for prostate cancer therapy. The Journal of Steroid Biochemistry and Molecular Biology. 125: 23-31. PMID 21092758 DOI: 10.1016/J.Jsbmb.2010.11.005  0.634
2010 Vasaitis TS, Njar VC. Novel, potent anti-androgens of therapeutic potential: recent advances and promising developments. Future Medicinal Chemistry. 2: 667-80. PMID 21426013 DOI: 10.4155/Fmc.10.14  0.631
2009 Brodie A, Njar V, Macedo LF, Vasaitis TS, Sabnis G. The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer. Urologic Oncology. 27: 53-63. PMID 19111799 DOI: 10.1016/J.Urolonc.2008.07.036  0.619
2008 Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya LK, Guo Z, Fang HB, Njar VC, Brodie AM. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Molecular Cancer Therapeutics. 7: 2348-57. PMID 18723482 DOI: 10.1158/1535-7163.MCT-08-0230  0.439
2008 Moreira VM, Vasaitis TS, Guo Z, Njar VC, Salvador JA. Synthesis of novel C17 steroidal carbamates. Studies on CYP17 action, androgen receptor binding and function, and prostate cancer cell growth. Steroids. 73: 1217-27. PMID 18582482 DOI: 10.1016/J.Steroids.2008.05.010  0.51
2008 Moreira VM, Salvador JAR, Vasaitis TS, Njar VCO. CYP17 inhibitors for prostate cancer treatment - An update Current Medicinal Chemistry. 15: 868-899. PMID 18473796 DOI: 10.2174/092986708783955428  0.494
2008 Purushottamachar P, Khandelwal A, Vasaitis TS, Bruno RD, Gediya LK, Njar VC. Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent. Bioorganic & Medicinal Chemistry. 16: 3519-29. PMID 18316193 DOI: 10.1016/J.Bmc.2008.02.031  0.637
2007 Moreira VM, Vasaitis TS, Njar VC, Salvador JA. Synthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17 inhibitors. Steroids. 72: 939-48. PMID 17884122 DOI: 10.1016/J.Steroids.2007.08.004  0.582
2007 Purushottamachar P, Khandelwal A, Chopra P, Maheshwari N, Gediya LK, Vasaitis TS, Bruno RD, Clement OO, Njar VC. First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents. Bioorganic & Medicinal Chemistry. 15: 3413-21. PMID 17383188 DOI: 10.1016/J.Bmc.2007.03.019  0.596
2006 Njar VC, Gediya L, Purushottamachar P, Chopra P, Vasaitis TS, Khandelwal A, Mehta J, Huynh C, Belosay A, Patel J. Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Bioorganic & Medicinal Chemistry. 14: 4323-40. PMID 16530416 DOI: 10.1016/J.Bmc.2006.02.041  0.373
2005 Handratta VD, Vasaitis TS, Njar VC, Gediya LK, Kataria R, Chopra P, Newman D, Farquhar R, Guo Z, Qiu Y, Brodie AM. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. Journal of Medicinal Chemistry. 48: 2972-84. PMID 15828836 DOI: 10.1021/Jm040202W  0.66
2004 Wang Q, Udayakumar TS, Vasaitis TS, Brodie AM, Fondell JD. Mechanistic relationship between androgen receptor polyglutamine tract truncation and androgen-dependent transcriptional hyperactivity in prostate cancer cells. The Journal of Biological Chemistry. 279: 17319-28. PMID 14966121 DOI: 10.1074/Jbc.M400970200  0.511
2003 Clement OO, Freeman CM, Hartmann RW, Handratta VD, Vasaitis TS, Brodie AM, Njar VC. Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy. Journal of Medicinal Chemistry. 46: 2345-51. PMID 12773039 DOI: 10.1021/Jm020576U  0.447
Show low-probability matches.